Beta Blockade in Critical Injury
Information source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Trauma
Intervention: Propranolol (Drug)
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Critically injured patients endure a period of hypermetabolism/catabolism after being
resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor
wound healing, susceptibility to infection and long hospital stays. While there have been
some data to suggest that hypermetabolism can be ameliorated in burn patients by beta
blockade, to our knowledge, a prospective trial in trauma patients has not yet been done.
Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose
control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of
critically injured patients.
Official title: Beta-Blockade Reduces Catabolism in Severely Injured Trauma Patients
Study design: Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Lean body mass
ICU length of stay
Minimum age: 18 Years.
Maximum age: N/A.
- ISS>25, stable at 48 hours after injury
- Fully resuscitated
Exclusion Criteria Include:
- Intracranial hypertension requiring active treatment
- Already on beta blocker for a standard indication
Locations and Contacts
Denver Health Medical Center, Denver, Colorado 80204, United States; Recruiting
Debi Talamonti, Phone: 303-436-5657, Email: firstname.lastname@example.org
Jeff Johnson, MD, Principal Investigator
Last updated: July 10, 2007